These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2207304)

  • 41. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men.
    Gajjar DA; LaCreta FP; Uderman HD; Kollia GD; Duncan G; Birkhofer MJ; Grasela DM
    Pharmacotherapy; 2000 Jun; 20(6 Pt 2):49S-58S. PubMed ID: 10850521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Penetration of lomefloxacin into human prostatic tissue.
    Leroy A; Humbert G; Fillastre JP; Grise P
    Am J Med; 1992 Apr; 92(4A):12S-14S. PubMed ID: 1374582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses.
    Mattina R; Bonfiglio G; Cocuzza CE; Gulisano G; Cesana M; Imbimbo BP
    Chemotherapy; 1991; 37(6):389-97. PubMed ID: 1662127
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration.
    Stass H; Kubitza D; Schühly U
    Clin Pharmacokinet; 2001; 40 Suppl 1():1-9. PubMed ID: 11352436
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison of the safety and efficacy of lomefloxacin and ciprofloxacin in the treatment of complicated or recurrent urinary tract infections.
    Cox CE
    Am J Med; 1992 Apr; 92(4A):82S-86S. PubMed ID: 1316077
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers.
    Allen A; Bygate E; Oliver S; Johnson M; Ward C; Cheon AJ; Choo YS; Kim IC
    Antimicrob Agents Chemother; 2000 Jun; 44(6):1604-8. PubMed ID: 10817716
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers.
    Teng R; Liston TE; Harris SC
    J Antimicrob Chemother; 1996 May; 37(5):955-63. PubMed ID: 8737145
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interaction of quinolones with the theophylline metabolism in man: investigations with lomefloxacin and pipemidic acid.
    Staib AH; Harder S; Fuhr U; Wack C
    Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):289-3. PubMed ID: 2737798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent.
    Wise R; Johnson J; O'Sullivan N; Andrews JM; Imbimbo BP
    J Antimicrob Chemother; 1991 Dec; 28(6):905-9. PubMed ID: 1667783
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intraprostatic distribution of lomefloxacin following multiple-dose administration.
    Kovarik JM; de Hond JA; Hoepelman IM; Boon T; Verhoef J
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2398-401. PubMed ID: 2088193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lomefloxacin clinical pharmacokinetics.
    Freeman CD; Nicolau DP; Belliveau PP; Nightingale CH
    Clin Pharmacokinet; 1993 Jul; 25(1):6-19. PubMed ID: 8394795
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A ten-laboratory study of lomefloxacin (NY-198 or SC 47111) antimicrobial activity in Argentina.
    Bianchini HN; Sarachian B; Fernandez A; Paolasso R; Kaufman C; Notario R; Porven G; Ingaramo RA; Perez S; Ferrero SM
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):45S-50S. PubMed ID: 2676328
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lomefloxacin, a new fluoroquinolone. Studies on in vitro antimicrobial spectrum, potency, and development of resistance.
    Aldridge KE; Henderberg A; Gebbia K; Schiro DD; Janney A; Sanders CV
    Diagn Microbiol Infect Dis; 1989; 12(3):221-33. PubMed ID: 2791485
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative in vitro activity of lomefloxacin, a difluoro-quinolone.
    Robbins MJ; Baskerville AJ; Sanghrajka M; Mumtaz G; Felmingham D; Ridgway GL; Grüneberg RN
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):65S-76S. PubMed ID: 2791500
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Prostatic tissue and fluid levels of lomefloxacin (NY-198)].
    Nasu Y; Nishitani Y; Yamada D; Hayata S; Tsugawa M; Kishi M; Mizuno A; Kumon H; Ohmori H; Nanba K
    Hinyokika Kiyo; 1989 Mar; 35(3):551-6. PubMed ID: 2735259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
    Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
    Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison of the photosensitizing potential of trovafloxacin with that of other quinolones in healthy subjects.
    Ferguson J; McEwen J; Al-Ajmi H; Purkins L; Colman PJ; Willavize SA
    J Antimicrob Chemother; 2000 Apr; 45(4):503-9. PubMed ID: 10747828
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The influence of age and gender on the pharmacokinetics of moxifloxacin.
    Sullivan JT; Lettieri JT; Liu P; Heller AH
    Clin Pharmacokinet; 2001; 40 Suppl 1():11-8. PubMed ID: 11352437
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multiple-dose pharmacokinetics and safety of oral amifloxacin in healthy volunteers.
    Cook JA; Silverman MH; Schelling DJ; Nix DE; Schentag JJ; Brown RR; Stroshane RM
    Antimicrob Agents Chemother; 1990 Jun; 34(6):974-9. PubMed ID: 2393295
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora.
    Ritz M; Lode H; Fassbender M; Borner K; Koeppe P; Nord CE
    Antimicrob Agents Chemother; 1994 Mar; 38(3):455-9. PubMed ID: 8203837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.